Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.

Vasan S, Foiles P, Founds H.

Arch Biochem Biophys. 2003 Nov 1;419(1):89-96. Review.

PMID:
14568012
2.

The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.

Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME.

FASEB J. 2003 Sep;17(12):1762-4. Epub 2003 Jul 18.

PMID:
12958202
3.

Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells.

M√ľnch G, Gasic-Milenkovic J, Dukic-Stefanovic S, Kuhla B, Heinrich K, Riederer P, Huttunen HJ, Founds H, Sajithlal G.

Exp Brain Res. 2003 May;150(1):1-8. Epub 2003 Mar 5.

PMID:
12698210
4.

Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.

Vasan S, Foiles PG, Founds HW.

Expert Opin Investig Drugs. 2001 Nov;10(11):1977-87. Review.

PMID:
11772301
5.

Active glycation in neurofibrillary pathology of Alzheimer disease: N(epsilon)-(carboxymethyl) lysine and hexitol-lysine.

Castellani RJ, Harris PL, Sayre LM, Fujii J, Taniguchi N, Vitek MP, Founds H, Atwood CS, Perry G, Smith MA.

Free Radic Biol Med. 2001 Jul 15;31(2):175-80.

PMID:
11440829
6.

Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol.

Al-Abed Y, Mitsuhashi T, Li H, Lawson JA, FitzGerald GA, Founds H, Donnelly T, Cerami A, Ulrich P, Bucala R.

Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2385-90.

7.

Tobacco smoke is a source of toxic reactive glycation products.

Cerami C, Founds H, Nicholl I, Mitsuhashi T, Giordano D, Vanpatten S, Lee A, Al-Abed Y, Vlassara H, Bucala R, Cerami A.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13915-20.

8.

Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia.

Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H.

Kidney Int. 1997 Dec;52(6):1645-50.

9.

Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity.

Mellinghoff AC, Reininger AJ, Wuerth JP, Founds HW, Landgraf R, Hepp KD.

Diabet Med. 1997 Oct;14(10):832-6.

PMID:
9371474
10.

Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs.

Stitt AW, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li YM, Bucala R, Vlassara H.

Mol Med. 1997 Sep;3(9):617-27.

11.

Standardizing the immunological measurement of advanced glycation endproducts using normal human serum.

Mitsuhashi T, Vlassara H, Founds HW, Li YM.

J Immunol Methods. 1997 Aug 22;207(1):79-88.

PMID:
9328589
12.

Long-term assessment of glucose control by haemoglobin-AGE measurement.

Wolffenbuttel BH, Giordano D, Founds HW, Bucala R.

Lancet. 1996 Feb 24;347(9000):513-5.

PMID:
8596270
13.

Serum advanced glycosylation end-products in patients on hemodialysis and CAPD.

Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW.

Perit Dial Int. 1995;15(2):129-33.

PMID:
7612732

Supplemental Content

Loading ...
Support Center